Shield Therapeutics - AEGIS-H2H update – non-inferiority at 24 weeks
Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study. The re-analysis demonstrates that...
210 Views
Shield Therapeutics - All eyes on a US partnering deal
Shield Therapeutics (STX) has reported FY19 results; total revenue of £0.7m reflects royalties on Feraccru sales from European partner Norgine....
139 Views
Shield Therapeutics - Next step a US partnering deal
Shield Therapeutics (STX) has provided an updated trading statement ahead of FY19 results, expected at the end of May. In its January trading...
208 Views
Shield Therapeutics - Tim Watts succeeds Carl Sterritt as CEO
Shield Therapeutics (STX) has announced that founder Carl Sterritt has resigned from his role as CEO with mutual agreement from its main...
223 Views
Shield Therapeutics - AEGIS-2 update
Shield Therapeutics (STX) has announced a technical update to findings from the AEGIS-H2H post-marketing study, which evaluated Feraccru/Accrufer...
643 Views